We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

36 hedge funds and large institutions have $28.5M invested in Spruce Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less funds holding

Funds holding: 43 → 36 (-7)

17% less capital invested

Capital invested by funds: $34.4M → $28.5M (-$5.86M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

60% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 15

Holders
36
Holders Change
-7
Holders Change %
-16.28%
% of All Funds
0.61%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
6
Reduced
15
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$325K
2
Morgan Stanley
Morgan Stanley
New York
+$84.2K
3
E
Ergoteles
New York
+$71.6K
4
Renaissance Technologies
Renaissance Technologies
New York
+$67.9K
5
MAM
Marquette Asset Management
Minnesota
+$39.7K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$638K
2
BCM
Bridgeway Capital Management
Texas
-$318K
3
JP Morgan Chase
JP Morgan Chase
New York
-$194K
4
State Street
State Street
Massachusetts
-$192K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$113K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$7.86M – – –
OFM
2
Omega Fund Management
Massachusetts
$3.76M – – –
RVM
3
RiverVest Venture Management
Missouri
$3.74M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$3M +$4.48K +35 +0.2%
RSCM
5
Rock Springs Capital Management
Maryland
$2.82M – – –
ACM
6
Aisling Capital Management
New York
$2.1M – – –
LGM
7
Logos Global Management
California
$1.74M – – –
SCV
8
Sands Capital Ventures
Virginia
$1.37M – – –
Millennium Management
9
Millennium Management
New York
$331K +$325K +2,535 New
BlackRock
10
BlackRock
New York
$272K -$638K -4,980 -71%
Renaissance Technologies
11
Renaissance Technologies
New York
$263K +$67.9K +530 +36%
Vanguard Group
12
Vanguard Group
Pennsylvania
$202K -$64.4K -503 -25%
State Street
13
State Street
Massachusetts
$162K -$192K -1,498 -55%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$161K -$40.5K -316 -20%
MAM
15
Marquette Asset Management
Minnesota
$112K +$39.7K +310 +57%
Morgan Stanley
16
Morgan Stanley
New York
$106K +$84.2K +657 +432%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$105K -$113K -884 -52%
BCM
18
Bridgeway Capital Management
Texas
$104K -$318K -2,484 -76%
Goldman Sachs
19
Goldman Sachs
New York
$104K +$29K +226 +40%
E
20
Ergoteles
New York
$73K +$71.6K +559 New
VF
21
Virtu Financial
New York
$27K +$26.9K +210 New
Northern Trust
22
Northern Trust
Illinois
$24K -$96.6K -754 -80%
SG
23
StoneX Group
New York
$20.7K +$20.4K +159 New
Barclays
24
Barclays
United Kingdom
$20K -$2.05K -16 -9%
UBS Group
25
UBS Group
Switzerland
$10K +$3.33K +26 +50%
1
2

SPRB Hedge Fund Activity: Q2 2022 in Review

36 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2022, worth a combined $28.5M — down 17% from $34.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of SPRB and 6 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 6 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $325K. The largest seller was BlackRock, cutting an estimated $638K.

  • 36 institutional investors held Spruce Biosciences (SPRB) as of Q2 2022, down from 43 in Q1 2022.
  • Funds reported $28.5M of Spruce Biosciences stock for Q2 2022, down 17% quarter-over-quarter.
  • 6 funds opened new Spruce Biosciences positions in Q2 2022 and 11 closed out, a net change of -5 holders.
  • The largest Spruce Biosciences buyer in Q2 2022 was Millennium Management, an estimated $325K added.
  • The largest Spruce Biosciences seller in Q2 2022 was BlackRock, an estimated $638K sold.

Based on aggregated 13F filings for Q2 2022.